A global dairy ingredient supplier wanted to know where its protein ingredients had enough clinical backing to support a health claim, and where competitors had not yet taken that claim.
The initial logic was straightforward: identify health benefits with strong published evidence, then check which benefits no competitor was selling against. Those gaps could indicate a commercial opportunity.
One benefit area appeared to be the clearest opportunity on paper. It had more clinical trials than any other area in the study, yet no product on the market was positioned around it.
It turned out to be the weakest opportunity in the set.
Counting Trials Is Not the Same as Reading Them
The benefit area had 18 human studies behind it. Most other areas had between two and five.
On a scoring framework covering trial intensity, consistency of outcomes, trial quality, and geographic diversity, it ranked near the top.
It also appeared to pass the commercial test. Searches across ingredient suppliers and finished brands found no supplier claiming the benefit and no consumer product positioned around it.
On paper, the combination looked like textbook whitespace: substantial evidence with no visible commercial claim.
The team then stopped counting the studies and reviewed what they actually showed.
The Direction of the Evidence Had Reversed
The early studies were small pilots and reported positive findings. They suggested that the ingredient could reduce a specific long-term health risk in a vulnerable population.
Those results were encouraging enough to justify a much larger trial.
That trial eventually enrolled more than 2,000 participants across 78 centres in 15 countries and followed them for more than a decade.
It found no effect. The intervention and control groups ended up in the same place.
The published conclusion was direct: the findings did not support changing dietary recommendations for the population studied.
This is what a trial count cannot capture. The small early studies pointed in one direction, while the larger, more definitive study pointed in the other. A framework that treats every study as one equivalent data point can therefore rank this area highly. Reviewing the underlying studies changes the picture.
The absence of products was therefore consistent with the later negative evidence rather than evidence of an overlooked market opportunity.
A Second Benefit Area Failed for a Completely Different Reason
A related benefit area showed a similar pattern at first: substantial evidence volume and no ingredient-level claim.
The commercial search told a different story. Products did exist, and they were widely sold with the health claim.
The claim was simply attributed to another ingredient.
Across three different manufacturers, the benefit was credited to added ingredients rather than to the protein itself. One brand credited an added oligosaccharide. Another credited a probiotic strain. A third credited a combination of oligosaccharides.
The most revealing detail appeared in a footnote on one of the packs. The supporting claim compared the product against the same formulation without the probiotic. The protein was identical in both arms, meaning it was held constant rather than being the component credited with the benefit.
The same attribution pattern appeared across three manufacturers. This suggested that the category had adopted a consistent approach to assigning the benefit.
For a supplier, this changes the whitespace question. The benefit was not unclaimed. It was already being claimed by another ingredient in the same product.
Regulation Explained Why the Convention Existed
The regulatory assessment provided another part of the explanation.
In this product category, health and nutrition claims are prohibited outright by regulation in a major market. The protein base falls under the restriction, while added ingredients can be assessed individually and can carry permitted statements.
That reframed the commercial search. Manufacturers were not necessarily choosing to credit the additives simply because they preferred those ingredients. The regulatory framework meant that the claim had to be routed through an ingredient that could carry it.
For a supplier entering the space, better science alone would therefore not resolve the issue. The major constraint was claim permissibility.
Assessment Approach: How GreyB Did It
1. Evidence Mapping Before Evidence Scoring
Every study was categorised by ingredient, benefit, industry vertical, study design, population, comparator, funding entity, and reported outcome.
Recording the comparator and outcome direction separately made the reversal visible. A study logged only as “positive” says little about what it was positive against or whether a later study changed the evidence base.
2. Weighting Studies Instead of Counting Them
A scoring framework was built across four parameters: trial intensity, consistency of outcomes, geographic diversity, and trial quality.
The scores were then reviewed against the underlying studies rather than accepted at face value.
This review layer caught both failing areas. Both initially scored highly. Both changed assessment after the underlying evidence was examined.
3. Separating Claim Absence From Claim Attribution
Commercial searches covered ingredient supplier documentation and finished consumer products, including on-pack claims, e-commerce listings, and technical datasheets.
Each claim found was logged against the ingredient to which it was attributed, rather than simply against the product in which it appeared.
This distinction surfaced the attribution pattern. A search that asks only whether a claim exists would have created a false whitespace gap.
4. Testing Permissibility, Not Just Availability
Every apparent gap was then checked against the claim frameworks of the relevant markets, including authorised claim registers, category-specific regulations, and documented regulatory challenges to similar claims.
This step distinguishes a commercial gap from a regulatory constraint. A commercial gap may warrant further investigation. A regulatory constraint requires a different question: whether the claim can legally be made at all.
What the Client Took Away
Two of the highest-scoring benefit areas in the study were removed from consideration.
That was not a failure of the analysis. It prevented evidence volume and apparent whitespace from being mistaken for commercial opportunity.
Both areas had characteristics that could have triggered further investment: a large evidence base, visible market relevance, and no obvious competitor claim at the ingredient level. Without the review layer, either could have led to further clinical investment before the underlying evidence or regulatory constraints became clear.
The study also produced a clearer test for the areas that did survive.
An opportunity now had to pass four filters:
- Is the evidence positive in direction, not just large in volume?
- Is the benefit unclaimed by any ingredient, not just by this one?
- Is the claim permissible in the target market?
- Does the published evidence apply to the supplier’s own material grade?
That changed the exercise from finding gaps to testing whether those gaps were actually actionable.That changed the exercise from finding gaps to testing whether those gaps were actually actionable.
Want to Test Your Health Claim Opportunities Before You Invest
Fill the form to share your requirements with our experts​